SST and neoplasm: The use of FDG to complement SST PET/CT has been suggested to fully characterize the whole tumor burden biology/heterogeneity by both demonstrating the SST‐expressing tumor component and by excluding the presence of FDG‐positive undifferentiated tumor clones that may ultimately drive the long‐term prognosis.